Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Myeloid Leukemia
100%
Philadelphia Chromosome
100%
BCR-ABL Inhibitors
100%
Dosing Schedule
100%
Treatment Optimization
100%
Imatinib
66%
Dasatinib
50%
Imatinib-resistant
33%
Treatment Efficacy
16%
Interferon-α (IFN-α)
16%
Treatment Options
16%
Acute Lymphoblastic Leukemia
16%
Second-generation Tyrosine Kinase Inhibitors
16%
Nilotinib
16%
Standard of Care
16%
Intolerant
16%
Twice Daily
16%
Daily Dose
16%
Imatinib Resistance
16%
BCR-ABL
16%
Dose Escalation
16%
Platelet-derived Growth Factor Receptor (PDGFR)
16%
Chronic Phase
16%
Treatment Safety
16%
Safety Profile
16%
Accelerated Phase
16%
Receptor-interacting Protein Kinase 1 (RIPK1)
16%
Tolerability
16%
Dosing Regimen
16%
Improved Outcomes
16%
Kinase Inhibitor
16%
All-phase
16%
Genetic Aberrations
16%
Efficacy Profile
16%
Once-daily
16%
New Therapeutic Approaches
16%
Imatinib Intolerance
16%
Oral Inhibitors
16%
Disease Pathophysiology
16%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Imatinib
100%
Chronic Myeloid Leukemia
100%
Philadelphia 1 Chromosome
100%
Abelson Kinase
100%
Dasatinib
42%
Myeloid Leukemia
28%
Diseases
14%
Phosphotransferase
14%
Acute Lymphoblastic Leukemia
14%
Nilotinib
14%
Interferon
14%
Pathophysiology
14%
Platelet Derived Growth Factor Receptor
14%
Phosphotransferase Inhibitor
14%
Tolerability
14%